Christopher J. Senner
Executive VP & CFOMr. Christopher J. Senner, also known as Chris, served as Independent Director of Quince Therapeutics, Inc. (formerly known as Cortexyme, Inc.) since March 2019 until October 8, 2026. Mr. Senner has been the Chief Financial Officer and Executive Vice President of Exelixis, Inc. since July 15, 2015. He is responsible for global finance function, controllership and operational financial planning and analysis, including research and development, manufacturing, commercial operations, tax and treasury planning at Exelixis, Inc. He has experience in biopharmaceutical finance, including deep expertise in global financial operations and controls, strategic planning and analysis, supply chain finance and business development. He served as Vice President of Corporate Finance at Gilead Sciences, inc a biopharmaceutical company, from March 2010 to July 2015, where he was accountable for controllership, tax, treasury and corporate and operational financial planning. Mr He spent eighteen years at Wyeth in a variety of financial roles with increasing responsibility for many of its divisions and regions and also served as its Chief Financial Officer of Wyeth’s U.S. pharmaceuticals business and the BioPharma Business Unit. Mr. Senner holds a B.S. in Finance from Bentley College.
Positions
- Company NameExelixis, Inc.Stock CodeEXELPositionExecutive VP & CFOColleagues
- SPStelios PapadopoulosCo-Founder & Independent Chair of the Board
- MMMichael M. MorrisseyCEO, President & Director
- BJBrenda J. HeftiSenior VP & General Counsel
- DTDana T. AftabExecutive Vice President of Research & Development
- JLJack L. WyszomierskiIndependent Director
- JAJulie Anne SmithIndependent Director
- MCMaria C. FreireIndependent Director
